Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee263
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee100
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial98
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis55
ATTRv amyloidosis Italian Registry: clinical and epidemiological data51
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis47
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines42
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation39
Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding30
Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis29
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen25
Association between spinal stenosis and wild-type ATTR amyloidosis25
Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging23
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma23
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies23
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group22
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres22
Next generation flow cytometry for MRD detection in patients with AL amyloidosis21
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients19
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients18
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis17
New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden16
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study16
The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease16
DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis16
Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis14
Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 1714
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience13
Dialysis-related amyloidosis associated with a novel β2-microglobulin variant13
A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis12
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis11
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure11
Proteomic analysis shows that the main constituent of subepidermal localised cutaneous amyloidosis is not galectin-79
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type9
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)9
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study9
Cardiac sympathetic denervation in wild-type transthyretin amyloidosis9
Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience9
The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis8
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays8
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy8
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis8
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial8
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)7
Subclinical retinal angiopathy associated with hereditary transthyretin amyloidosis – assessed with optical coherence tomography angiography7
The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients7
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease7
Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series7
Early events in light chain aggregation at physiological pH reveal new insights on assembly, stability, and aggregate dissociation6
Two types of systemic amyloidosis in a single patient6
Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis6
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis6
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
Full-length TDP-43 and its C-terminal domain form filaments in vitro having non-amyloid properties6
CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis6
Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant6
EGF-containing fibulin-like extracellular matrix protein 1 amyloid incidentally found in surgically resected specimens of Colon cancer: a case report emphasising on an unrecognised type5
Anticipation on age at onset in kindreds with hereditary ATTRV30M amyloidosis from the Majorcan cluster5
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis5
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis5
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study5
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation5
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre5
Binding of serum-derived amyloid-associated proteins to amyloid fibrils5
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study5
Enhanced detection of ATTR amyloid using a nanofibril-based assay4
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis4
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy4
Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria4
A case of novel amyloidosis: glucagon-derived amyloid deposition associated with pancreatic neuroendocrine tumour4
Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis4
Complement 9 in amyloid deposits4
In search of the most effective therapy for light chain amyloidosis4
Quantitative proteome profiling provides evidence of an activation of the complement cascade in ATTR amyloidosis4
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage4
Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis4
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis4
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution4
Cardiac manifestations in Finnish gelsolin amyloidosis patients4
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis4
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain3
Apolipoprotein AI amyloid deposits in the ligamentum flavum in patients with lumbar spinal canal stenosis3
Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response3
Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival3
When to suspect transthyretin amyloidosis in cases of isolated vitreous opacities?3
Electrochemical skin conductance values suggest frequent subclinical autonomic involvement in patients with AL amyloidosis3
Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis3
AA amyloidosis in inflammatory active malignant paraganglioma3
From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis3
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?3
Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue3
Mass spectrometry-based proteomic analysis of parathyroid adenomas reveals PTH as a new human hormone-derived amyloid fibril protein3
Renal calcitonin amyloidosis in a patient with disseminated medullary thyroid carcinoma3
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy3
Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank3
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis2
Alterations in multi-layer strain in AL amyloidosis2
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal2
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies2
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange2
Utilization and tolerance of beta-blockers among patients with AL amyloidosis2
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up2
Management of AL amyloidosis in 2021+2
Heterogeneous worldwide access and pricing of Tafamidis2
Survey of amyloidosis cases among different free-living wild and zoo animals2
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis2
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis2
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours2
0.023038148880005